Theravance Biopharma, Inc. 4

CEO Rick E. Winningham had 20,034 Theravance Biopharma ordinary shares withheld for taxes upon RSU vesting at $16.95 per share, retaining over 1.6 million shares directly plus additional indirect holdings.

On 2026-08-20, Theravance Biopharma, Inc. CEO Rick E. Winningham had 20,034 ordinary shares withheld by the issuer at a price of $16.95 per share to satisfy tax obligations arising from the vesting of previously granted restricted stock units, a non-open-market transaction recorded as a disposition. Following this tax withholding, he continued to hold 1,611,022 ordinary shares directly, plus additional indirect holdings of 23,400 shares held as custodian and 92,567 shares held by trust. The transaction reflects routine equity compensation tax settlement rather than a discretionary purchase or sale in the open market.

Filing Facts

CIK

1583107

Ticker

TBPH

Form

4

Source Type

fda

Accession

0001302443-26-000012

Alert Tier

5